GALENA BIOPHARMA, INC. (NASDAQ:GALE) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition.
|
company) issued a press release announcing our financial results
for the three months ended March 31, 2017 and providing an update
on recent business developments. A copy of the press release is
attached to this Report as Exhibit 99.1 and is incorporated
herein by reference.
accompanying Exhibit 99.1, shall not be deemed to be filed for
the purposes of Section 18 of the Securities Exchange Act of
1934, as amended, (the Exchange Act), or otherwise subject to the
liabilities of such section, nor shall such information be deemed
to be incorporated by reference in any filing by the company
under the Securities Act of 1933, as amended, or the Exchange
Act, regardless of the general incorporation language of such
filing, except as specifically stated in such filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
Exhibit No.
|
Description
|
||
|
99.1
|
Press Release of Galena Biopharma, Inc. dated May 10,
2017. |
||
About GALENA BIOPHARMA, INC. (NASDAQ:GALE)
Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company’s NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company’s therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient’s own immune system to seek out and attack any residual cancer cells. GALENA BIOPHARMA, INC. (NASDAQ:GALE) Recent Trading Information
GALENA BIOPHARMA, INC. (NASDAQ:GALE) closed its last trading session up +0.025 at 0.614 with 297,145 shares trading hands.
